Vincerx Pharma, Inc.
VINC
$0.05
-$0.005-9.09%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.32M | 3.16M | 3.89M | 3.61M | 2.92M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.33M | 6.43M | 7.79M | 7.37M | 7.48M |
| Operating Income | -3.33M | -6.43M | -7.79M | -7.37M | -7.48M |
| Income Before Tax | -5.00M | -7.99M | -7.84M | -1.81M | -12.43M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.00M | -7.99M | -7.84M | -1.81M | -12.43M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.00M | -7.99M | -7.84M | -1.81M | -12.43M |
| EBIT | -3.33M | -6.43M | -7.79M | -7.37M | -7.48M |
| EBITDA | -3.32M | -6.41M | -7.78M | -7.35M | -7.47M |
| EPS Basic | -1.40 | -3.57 | -5.00 | -1.21 | -11.46 |
| Normalized Basic EPS | -0.87 | -1.56 | -3.12 | -0.76 | -7.16 |
| EPS Diluted | -1.40 | -3.57 | -5.00 | -1.21 | -11.46 |
| Normalized Diluted EPS | -0.87 | -1.56 | -3.12 | -0.76 | -7.16 |
| Average Basic Shares Outstanding | 3.58M | 2.24M | 1.57M | 1.49M | 1.09M |
| Average Diluted Shares Outstanding | 3.58M | 2.24M | 1.57M | 1.49M | 1.09M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |